Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas

Wilfredo Alejandro González-Arriagada*, Isaac E. García, René Martínez-Flores, Sebastián Morales-Pison, Ricardo D. Coletta

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The interaction between malignant cells and the tumor microenvironment is critical for tumor progression, and the chemokine ligand/receptor axes play a crucial role in this process. The CXCR4/CXCL12 and CCR5/CCL5 axes, both related to HIV, have been associated with the early (epithelial–mesenchymal transition and invasion) and late events (migration and metastasis) of cancer progression. In addition, these axes can also modulate the immune response against tumors. Thus, antagonists against the receptors of these axes have been proposed in cancer therapy. Although preclinical studies have shown promising results, clinical trials are needed to include these drugs in the oncological treatment protocols. New alternatives for these antagonists, such as dual CXCR4/CCR5 antagonists or combined therapy in association with immunotherapy, need to be studied in cancer therapy.

Original languageEnglish
Article number478
JournalInternational Journal of Molecular Sciences
Issue number1
StatePublished - 28 Dec 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors.


  • cancer therapy
  • chemokines
  • immunotherapy
  • oncology


Dive into the research topics of 'Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas'. Together they form a unique fingerprint.

Cite this